To order this report: Glucocorticoid-Induced Osteoporosis
Global Clinical Trials Review, H1, 2014 http://www.
Teriparatide is used in the management of osteoporosis, but only for specific indications-these include failed anti-resorptive therapy, severe fracturing disease, and glucocorticoid-induced osteoporosis
with a markedly decreased BMD.
Ultrastructural characteristics of glucocorticoid-induced osteoporosis
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
Clinical review 83: Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
Today's decision by the CHMP brings us one step closer to providing teriparatide as a treatment option for patients suffering from glucocorticoid-induced osteoporosis
PTH (1-34) in combination with hormone replacement therapy was also effective in increasing spinal bone density in women with glucocorticoid-induced osteoporosis
LOUIS -- Bisphosphonates remain underutilized in the prevention of glucocorticoid-induced osteoporosis
, despite national clinical guidelines that recommend their use in patients on long-term oral steroid therapy, Rosemarie Liu, M.
The iatrogenic form of glucocorticoid-induced osteoporosis
, which is more frequent than Cushing syndrome, has uncertain cellular and molecular bases.
Currently, there are no head-to-head data comparing the efficacy, overall safety, and tolerability of risedronate and alendronate in the treatment of postmenopausal or glucocorticoid-induced osteoporosis
Treatment of glucocorticoid-induced osteoporosis
in men and women receiving glucocorticoids in a daily dosage equivalent to 7.
(GIOP) is a ubiquitous complication of protracted glucocorticoid therapy.
SAN DIEGO--Teriparatide has received a boost in status as a preferentially effective treatment for glucocorticoid-induced osteoporosis
in the form of a second, confirmatory, randomized double-blind trial demonstrating the anabolic agent produces substantially greater increases in bone mineral density compared with a bisphosphonate.
Clinically, vitamin K2 sustains the lumbar bone mineral density (BMD) and prevents osteoporotic fractures in patients with age-related osteoporosis, prevents vertebral fractures in patients with glucocorticoid-induced osteoporosis
, increases the metacarpal BMD in the paralytic upper extremities of patients with cerebrovascular disease, and sustains the lumbar BMD in patients with liver-dysfunction-induced osteoporosis.
Epidemiology of glucocorticoid-induced osteoporosis